New Opportunities for Diabetes Mellitus Treatment

Authors

  • N.O. Kravchun SI «Institute of Endocrine Pathology Problems named after V.Ya. Danilevsky of NAMS of Ukraine», Kharkiv, Ukraine http://orcid.org/0000-0002-1039-4045
  • I.P. Romanova SI «Institute of Endocrine Pathology Problems named after V.Ya. Danilevsky of NAMS of Ukraine», Kharkiv, Ukraine
  • T.M. Tykhonova SI «Institute of Endocrine Pathology Problems named after V.Ya. Danilevsky of NAMS of Ukraine», Kharkiv, Ukraine
  • I.V. Chernyavska SI «Institute of Endocrine Pathology Problems named after V.Ya. Danilevsky of NAMS of Ukraine», Kharkiv, Ukraine
  • O.O. Gasanova SI «Institute of Endocrine Pathology Problems named after V.Ya. Danilevsky of NAMS of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.22141/2224-0721.6.54.2013.84641

Keywords:

diabetes mellitus, insulin

Abstract

The paper presents the results of the study of the efficiency and safety of the insulins Insuman® Rapid, Insuman® Basal, Insuman® Comb 25 in patients with type 2 diabetes mellitus. Those medications were found to have high hypoglycemic activity in combination with hypoglycemic tablets. The medications have a good tolerance and are safe.

Downloads

Download data is not yet available.

References

Мищенко Н. Санофи в партнерстве с компанией «Фарма Лайф» запустили производство инсулина Инсуман в Украине [Текст] / Н. Мищенко // Здоров’я України. — 2011. — № 2. — С. 28-29.

Kozak B.M. International Diabetes Federation (IDF) highlights growing global impact of diabetes in 5th edition of the Diabetes Atlas [Text] / B.M. Kozak, M.Y. Tjota, K.L. Close // Journal of Diabetes. — 2012. — Vol. 4. — P. 8-17.

Чернобров А.Д. Довідник основних показників діяльності ендокринологічної служби України за 2012 рік [Текст] / А.Д. Чернобров // Ендокринологія. — 2013. — Т. 18, № 1. — 36 с.

Кушнарева Н.Н. Опыт использования инсулина Инсуман® Базал и Инсуман® Комб 25 в лечении больных сахарным диабетом 2-го типа [Текст] / Н.Н. Кушнарева, В.В. Корпачев, А.В. Ковальчук // Міжнарод. ендокринол. журнал. — 2012. — № 7(47). — С. 77-81.

Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy (InsumanC25CN).

Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes (SPIRIT). Verified September 2012 by Sanofi Aventis.

Laubach E. Neutral protamine Hagedorn insulin [Text] / E. Laubach, P. Schwandt, M.M. Ritter // Lancet. — 2000. — Vol. 355. — P. 236.

NPH insulin administrationby means of a pen injector [Text] / J.O. Jorgensen, A. Flyvbjerg, J.T. Jorgensen [et al.] // Diabet. Med. — 1998. — Vol. 55. — P. 574-576.

Fisken R.A. Treatment of insulin-dependent diabetes using an injection pen: control, problems and patients preferences [Text] / R.A. Fisken, J. Goulbourn // Diabetes Res. — 1989. — Vol. 11. — P. 195-197.

Published

2022-02-21

How to Cite

Kravchun, N., Romanova, I., Tykhonova, T., Chernyavska, I., & Gasanova, O. (2022). New Opportunities for Diabetes Mellitus Treatment. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), (6.54), 77–79. https://doi.org/10.22141/2224-0721.6.54.2013.84641

Issue

Section

To practicing Endocrinologists

Similar Articles

1 2 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>